• Text size      
  • Send this article to a friend
  • Print this article

Alzheimer's major drug trial optimism

A major trial has been launched testing a new Alzheimer's drug designed to target the root cause of the disease.

The drug, MK-8931, suppresses production of molecular building blocks that create toxic protein in the brain.

Deposits of amyloid beta protein are thought to be the chief underlying cause of Alzheimer's.

The four-year Phase II/III Epoch study will eventually enrol up to 1700 patients from around the world.

Dr Richard Perry, one of the trial investigators from Imperial College NHS Trust, said: "It is important that there's still a focus on Alzheimer's research and it is encouraging to see research being undertaken to bring new treatment options to patients in the future."

Dr Paul Robinson, medical director of the UK arm of drug manufacturer MSD (Merck & Co), said: "Although MK-8931 is very early in development and a long way off being licensed, taking promising potential treatments for Alzheimer's disease into phase II/III is a very important milestone."

Dr Eric Karran, from the charity Alzheimer's Research UK, said: "It takes many years of research in the lab before a clinical trial can begin, and it's great to see research into potential new treatments for Alzheimer's disease progressing in this way."

Contextual targeting label: 

Commenting & Moderation

We moderate all comments on HeraldScotland on either a pre-moderated or post-moderated basis.
If you're a relatively new user then your comments will be reviewed before publication and if we know you well and trust you then your comments will be subject to moderation only if other users or the moderators believe you've broken the rules

Moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours. Please be patient if your posts are not approved instantly.